Please use this identifier to cite or link to this item: https://repositorio.ufrn.br/jspui/handle/123456789/25422
Title: Comparative Bioavailability of Two Extemporaneous Solid Formulations of Carbamazepine against the Innovator in Mexican Healthy Subjects
Authors: Araujo, Aurigena Antunes de
Guerra, Gerlane Bernardo Coelho
Solon, Lílian Grace da Silva
Dibildox, Estela
Perez-Urizar, Jose
Escobedo-Moratilla, Abraham
Torres-Roque, Irma
Martinez-Delgado, Maricela
Zapata-Morales, Juan Ramon
Soares, Luiz Alberto Lira
Covarrubias-Pinedo, Amador
Keywords: Carbamazepine;Pharmacokinetics;Anti-epileptics;HPLC;Bioavailability;Bioequivalence
Issue Date: 4-Mar-2014
Publisher: OMICS International
Citation: ARAÚJO, Aurigena Antunes de et al. Comparative Bioavailability of Two Extemporaneous Solid Formulations of Carbamazepine against the Innovator in Mexican Healthy Subjects. Journal of Bioequivalence & Bioavailability, v. 6, p. 033-037, 2014. Disponível em: <https://www.omicsonline.org/open-access/comparative-bioavailability-of-two-extemporaneous-solid-formulations-of-carbamazepine-against-the-innovator-in-mexican-healthy-subjects-jbb.1000177.php?aid=25060>. Acesso em: 19 mar. 2018.
Portuguese Abstract: Extemporaneous or off-label prescribing is not illegal and may sometimes be clinically and economically appropriate. However it is associated with a number of clinical, safety and ethical issues. Bioequivalence of these products must be proven before they are used in place of patent medicines. In the present study, a single-center, open, randomized, single-dose, 2-period crossover, 2-sequences pilot assay (two subgroups with n=6) was carried out to evaluate the bioavailability of two extemporaneous capsule of carbamazepine (200 mg): A-Formula® (A); and Formule® (B) in comparison to a tablet of the innovator product Tegretol® (C). Twelve healthy volunteers were randomly assigned to one of two arms to receive one test/reference formulation and following a two week wash-out period they received the other compound. Blood sampling was performed over 72 hours after dosing and levels of carbamazepine were determined by HPLC. Main findings of the study include that peak of plasma carbamazepine was faster following the extemporaneous capsules as compared to reference (Tmax: A: 6.58 h; B: 4.83 h vs 8.25-10.00 h, respectively), although no changes was observed in Cmax (A: 3.32 μg/mL; B: 3.10 μg/mL vs C: 3.14-2.85 μg/mL) neither in AUC0-t (A: 116.34 μg*h/mL; B: 145.66 μg*h/mL vs C: 123.18-138.37 μg*h/mL). The elimination half-life that ranged between 38.64-61.29 h but not difference were observed between all formulations. By using bioequivalence statistics it appears that A-Formula® or Formule® is bioequivalent to Tegretol® in terms of AUC0-t but not regarding Cmax. In conclusion, we demonstrated that two extemporaneous capsules of carbamazepine, A-Formula® and Formule® show similar concentration-time profiles to the reference tablet of immediate Tegretol®, however further studies with longer sample size are needed to confirm its bioequivalence and interchangeability.
URI: https://repositorio.ufrn.br/jspui/handle/123456789/25422
ISSN: 0975-0851
Appears in Collections:CB - DBF - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
Comparative Bioavailability of Two Extemporaneous_2014.pdf982,16 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.